Analysts cite USD 67.67 target for Prestige Consumer Healthcare stock

Published on 10/17/2026 at 19:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 265.71 million in fiscal 2027's first quarter. Prestige Consumer Healthcare stock was USD 49.92 on October 16, 2026, up 1.46 percent.

Analyst target and earnings date

MarketBeat cited a USD 67.67 consensus target on October 16, 2026.
Fiscal 2027 first-quarter revenue reached USD 265.71 million.
Prestige Consumer Healthcare stock was USD 49.92 at 4:00 p.m. EDT on October 16, 2026, up 1.46 percent versus the NYSE prior close.
Fiscal 2027 second-quarter results are scheduled for November 5, 2026.

PBH, US74112D1019, Illustration mit AI erstellt.

Analyst expectations put Prestige Consumer Healthcare in a higher valuation bracket, with a USD 67.67 consensus target cited on October 16, 2026. According to MarketBeat, five analysts cover the stock, with ratings ranging from Strong Buy to Sell and a consensus Hold rating. Prestige Consumer Healthcare last traded at USD 49.92 on October 16, 2026 at 4:00 p.m. EDT, up 1.46 percent versus the NYSE prior close of USD 49.20.

Revenue sets the operating baseline

The latest reported quarter delivered a concrete operating comparison. Prestige Consumer Healthcare generated USD 265.71 million in revenue in the first quarter of fiscal 2027, up 6.50 percent from USD 249.50 million in the year-ago quarter. The company also reported adjusted earnings per share of USD 0.98, compared with a USD 0.89 consensus estimate, according to MarketBeat. The comparison matters because the USD 67.67 target stands 35.58 percent above the October 16 price, calculated in the same currency.

Price position and valuation

The stock ended the latest NYSE session at USD 49.92, within a 52-week range of USD 42.62 to USD 71.07. The latest level is 29.74 percent below the 52-week high and 17.13 percent above the low. Trading volume reached 580,659 shares against an average of 556,395, while the price-to-earnings ratio was 13.98 and market capitalization was USD 2.4 billion.

Results date is November 5

Prestige Consumer Healthcare is scheduled to release fiscal 2027 second-quarter and first-half results before the market opens on November 5, 2026. The company also plans an 8:30 a.m. ET conference call, as reported by StockTitan. That date is the next clearly scheduled checkpoint for the revenue trajectory and the company's fiscal-year outlook.

Comparison with peers

October 16 market figures:
Prestige Consumer Healthcare (NYSE, USD): plus 1.46 percent, P/E 13.98, market capitalization USD 2.4 billion
Church & Dwight (NYSE, USD): plus 1.41 percent, P/E 33.72, market capitalization USD 24.8 billion
Perrigo (NYSE, USD): plus 0.91 percent, P/E minus 1.33, market capitalization USD 2.3 billion

Investor reference points

The price move was positive but smaller than the distance to the consensus target, leaving the scheduled November report as the next date capable of changing the earnings narrative. Prestige Consumer Healthcare sells over-the-counter health and personal-care products through brands including Dramamine, Clear Eyes, Compound W and Monistat.